The NWHN’s Written Testimony to the FDA Regarding Over-The-Counter Authorization of Opill, an Oral Contraceptive
Read the NWHN's testimony to the FDA in support of OPILL, an oral contraceptive, being approved for over-the-counter dispensation.
As a Breast Cancer Survivor, I’ve Seen Firsthand How Early Detection and Clinical Trial Initiatives Save Lives
For press inquiries about this op-ed, contact Director of Communications Adele Costa at [email protected] or by phone at 631 – 538 – 6348
Senate Hearing – the Women’s Health Protection Act (WHPA)
Read the NWHN's written testimony in support of the WHPA.
FDA Comments- Makena
[FDA-2019-N-4203] To Whom It May Concern: The National Women’s Health Network (NWHN) is a nonprofit advocacy organization that works to improve the health of all women. We are supported by our members and by choice, we do not accept financial support from drug companies or medical device manufacturers. We bring the voices, concerns and needs of women consumers to policy and regulatory tables. The NWHN encourages the Food and Drug…
FDA Meeting – Surgical Mesh for Transvaginal Repair of Pelvic Organ Prolapse
Testimony regarding surgical mesh and pelvic organ prolapse, delivered at the meeting of the FDA obstetrics and gynecology devices panel.
Getting an IUD: How One Size Does Not Fit All
In college, getting a long-acting reversible contraceptive (LARC) was in vogue. It seemed like everywhere I went, women were talking about how their IUD had changed their life for the better.
FDA Scientific Workshop – Female Sexual Interest/Arousal Disorder
Food and Drug Administration Scientific Workshop on Female Sexual Interest/Arousal Disorder